DarioHealth (NASDAQ:DRIO) Stock Rating Upgraded by Wall Street Zen

DarioHealth (NASDAQ:DRIO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a report on Wednesday, October 8th. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research note on Friday. Finally, Cowen reissued a “hold” rating on shares of DarioHealth in a research report on Friday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $32.00.

DarioHealth Stock Performance

DRIO opened at $11.73 on Friday. The stock’s 50 day simple moving average is $12.61 and its 200-day simple moving average is $12.69. The company has a current ratio of 3.30, a quick ratio of 2.83 and a debt-to-equity ratio of 0.48. The stock has a market cap of $26.69 million, a PE ratio of -0.89 and a beta of 1.19. DarioHealth has a 1 year low of $5.93 and a 1 year high of $31.00.

Hedge Funds Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd grew its position in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,511 shares of the company’s stock after buying an additional 43,513 shares during the quarter. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 as of its most recent filing with the Securities and Exchange Commission. 33.39% of the stock is owned by hedge funds and other institutional investors.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.